Prostate Cancer

Inter-reader agreement of the PI-QUAL score for prostate MRI quality in the NeuroSAFE PROOF trial. August 3, 2021

Androgen deprivation therapy and radiation for prostate cancer-cognitive impairment, sleep, symptom burden: a prospective study. August 3, 2021

Role of multiparametric MRI in long-term surveillance following focal laser ablation of prostate cancer. August 3, 2021

The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancer. August 3, 2021

Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer. August 3, 2021

Lantheus Announces the First and Only FDA Cleared AI-Enabled PSMA Digital Application, aPROMISE™ August 2, 2021

The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer after Radical Prostatectomy. August 2, 2021

An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer. August 2, 2021

177Lutetium PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castrate-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial. August 2, 2021

Activation of the ABCB1-amplicon promotes cellular viability and resistance to docetaxel and cabazitaxel in castration-resistant prostate cancer. August 2, 2021

A comprehensive assessment of 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients. August 2, 2021

Defining candidate mRNA and protein EV biomarkers to discriminate ccRCC and pRCC from non-malignant renal cells in vitro. August 2, 2021

Immunotherapy Combined With Radiation Therapy for Genitourinary Malignancies. August 2, 2021

Impact of positive surgical margin status in predicting early biochemical recurrence after robot-assisted radical prostatectomy. July 30, 2021

A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. July 30, 2021

Robotic-assisted radical prostatectomy with the Senhance® robotic platform: single center experience. July 30, 2021

Estimating the rate of overdiagnosis with prostate cancer screening: evidence from the Finnish component of the European Randomized Study of Screening for Prostate Cancer. July 30, 2021

Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials. July 29, 2021

Cardiovascular toxicities associated with abiraterone compared to enzalutamide-A pharmacovigilance study. July 29, 2021

Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients. July 29, 2021

Page 1 of 1165